Yazar "Keleş, Ayse Nur" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Ecballium elaterium extract reduces fibrosis during wound healing in rats(Taylor & Francis, 2021) İbiloğlu, İbrahim; Alabalık, Ulaş; Keleş, Ayse Nur; Aydoğdu, Gülay; Başuguy, Erol; Büyükbayram, HüseyinWe explored the effects of subcutaneously injected Ecballium elaterium (L) A. Rich. (EE) extract on skin wound-healing in rats, as well as the effects on the liver and pancreas. Twenty-eight rats were divided into two groups of 14 each: a saline control group (S) and an EE group. Both groups were divided into two subgroups according to the day of sacrifice (S-7 and S-14, and EE-7 and EE-14). All animals received 2.5 cm skin incisions followed by subcutaneous injections of either saline or 2.5 mg/kg EE per margin (5 mg/kg in total). The S and EE groups were compared in terms of the severity and type of local and neighbouring inflammation, vascularization, fibrosis and effects on the liver and pancreas. In addition, apoptosis and vascularity between S and EE groups were compared immunohistochemically with caspase-3 and cd-34 antibodies. There was no significant difference between the staining rates of caspase-3 and cd-34 in the immunohistochemical assay between the S and E groups. Subcutaneous EE was not toxic to the pancreas or liver; the EE-14 group exhibited less fibrosis than the S-14 group. Therefore, it can contribute to the proper closure of the lesion by reducing fibrosis during wound healing.Öğe Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes(Taylor & Francis Ltd, 2024) Dicleli, Medine; Keleş, Ayse Nur; Alabalık, UlaşMalignant Mesothelioma is a primary malignant tumor of the mesothelium lining the pleura, pericardium, peritoneum and tunica vaginalis of the testis with a poor prognosis. The epithelioid subtype is graded as high and low grade in the 2021 WHO classification of thoracic tumors. Recently, promising results from clinical trials of treatment with immune checkpoint inhibitors are reported. The aim of our study was to shed light on clinical studies on potential immune checkpoint inhibitors by examining VISTA and PD-L1 expression levels as well as HEG1 in malignant mesothelioma subtypes. Our study included 69 cases diagnosed with 'malignant mesothelioma, well-differentiated papillary mesothelial tumor, atypical mesothelial hyperplasia' at Dicle University Faculty of Medicine Department of Pathology between 2015 and 2021. Primary antibodies against HEG1, VISTA, and PD-L1 were used in the immunohistochemical study. The results showed a significant relationship between PD-L1 expression and sarcomatoid and high-grade epithelioid malignant mesotheliomas. VISTA was detected at a high rate in epithelioid malignant mesotheliomas and was negative in non-mesothelial tumors. HEG1 was positively monitored in mesothelial-derived tumors and negatively monitored in non-mesothelial tumors. The obtained results suggest that HEG1 could be further explored as a useful marker in determining mesothelial origin and that the expression levels of VISTA and PD-L1 markers may vary in histological subtypes in the selection of drugs for the treatment of malignant mesothelioma.